Welcome to Matter’s 2026 Planning kick off, where we discuss some of the core insights we shared with clients this year and what is coming next. To work with us for your 2026 planning season, contact: [email protected] 🔎More than 10% of Americans have already taken GLP-1 - American Psychological Association 🔎GLP-1 drug prescriptions for adults with commercial insurance increased by 364% from 2019 to 2024. - FAIR Health Study 🔎Since 2021, at least 50% of consumers define “beauty” as “looking healthy.” 44% of consumers define beauty as taking care of the mind and body. - McKinsey & Company 🔎In the U.S., “better appearance” shifted from the sixth-most-important dimension of health and wellness for Gen Z consumers in 2023 to the third in 2024. - McKinsey & Company 🔎53% of U.S. adults now say they are at least ‘somewhat concerned’ about the effects of PFAS, up from 47% in June of last year. - Civic Science 🔎The global biohacking market is projected to grow at a compound annual growth rate of more than 20% through 2030. - Grand View Research 🔎The global genetics testing market is projected to reach a valuation of $50 billion by 2033, up from $21 billion in 2024. - Grand View Research